Assignee
OCUPHIRE PHARMA INC
US·11 granted patents·6 pending applications·93 citations·filing 2017–2024
Top patents by PatentIndex Score
17 records- 0198US11566005B2Highly pure phentolamine mesylate and methods for making sameOCUPHIRE PHARMA INC·Filed 2022·Granted Jan 31, 2023·8 cites·21 claims
- 0297US11717510B2Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performanceOCUPHIRE PHARMA INC·Filed 2021·Granted Aug 8, 2023·6 cites·21 claims
- 0397US10772829B2Aqueous ophthalmic solutions of phentolamine and medical uses thereofOCUPHIRE PHARMA INC·Filed 2019·Granted Sep 15, 2020·13 cites·35 claims
- 0496US11976044B2Highly pure phentolamine mesylateOCUPHIRE PHARMA INC·Filed 2022·Granted May 7, 2024·4 cites·25 claims
- 0596US11000509B2Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performanceOCUPHIRE PHARMA INC·Filed 2017·Granted May 11, 2021·11 cites·27 claims
- 0695US11844858B2Aqueous ophthalmic solutions of phentolamine and medical uses thereofOCUPHIRE PHARMA INC·Filed 2021·Granted Dec 19, 2023·6 cites·22 claims
- 0795US10278918B2Aqueous ophthalmic solutions of phentolamine and medical uses thereofOCUPHIRE PHARMA INC·Filed 2017·Granted May 7, 2019·18 cites·23 claims
- 0894US12016841B2Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disordersOCUPHIRE PHARMA INC·Filed 2022·Granted Jun 25, 2024·4 cites·14 claims
- 0994US11400077B2Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disordersOCUPHIRE PHARMA INC·Filed 2020·Granted Aug 2, 2022·6 cites·24 claims
- 1094US11090261B2Aqueous ophthalmic solutions of phentolamine and medical uses thereofOCUPHIRE PHARMA INC·Filed 2019·Granted Aug 17, 2021·9 cites·18 claims
- 1194US10993932B2Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disordersOCUPHIRE PHARMA INC·Filed 2020·Granted May 4, 2021·8 cites·26 claims
- 1283US2024050412A1Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performanceOCUPHIRE PHARMA INC·Filed 2023·Application pending·0 cites
- 1378US2024308967A1Highly pure phentolamine mesylate and methods for making sameOCUPHIRE PHARMA INC·Filed 2024·Application pending·0 cites
- 1473US2021346349A1Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disordersOCUPHIRE PHARMA INC·Filed 2021·Application pending·0 cites
- 1566US2024101505A1Salts and esters of apx3330 and therapeutic uses thereofOCUPHIRE PHARMA INC·Filed 2023·Application pending·0 cites
- 1655US2024216334A1Methods and compositions for treating mydriasis, glaucoma, and other ocularconditionsOCUPHIRE PHARMA INC·Filed 2022·Application pending·0 cites
- 1749US2024216315A1Methods and compositions for treatment of diabetic retinopathy and related conditionsOCUPHIRE PHARMA INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when OCUPHIRE PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →